Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,410 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- A Systematic Review and Meta-Analysis of Surgical Feasibility and Outcomes Following Neoadjuvant Immune Checkpoint Inhibition in Resectable Stage III and IV Melanoma.
Read T, Nair G, Velli G, David M, Bayley G, Xu W, Barbour A, Smithers BM, Atkinson V. · Ann Surg Oncol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials.
Polito MG, Sisca L, Caruso D, Cosimati A, Ramirez Reinaga CA, Leka E, Santini D, Spinelli GP. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports.
Godin SL, Kingma T, Pillai A, Kholoki O, Kim AS. · Cancer Rep (Hoboken) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.
Aleid M, Aleid F, Allbdi D, Rchdeih A, Almuteri D, Almesned A, Alotab S, AlMishary Y, Alsamman G, Abusanad A. · Oncotarget · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.
Potter L, Lopez-Olivo MA, Uppal RS, Beeler D, Thong MSY, Phan B, Chou YJ, Krause K, Tanveer A, Hussain HU, Khan M, Abdel-Wahab N, Manzullo E, Kleckner AS, Escalante C. · Support Care Cancer · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV. · Lancet Oncol · 2026 · cited 2 timesclinical trial, phase iii, multicenter study
- Immune checkpoint inhibitors in the management of oral mucosal melanoma.
Paavilainen N, Degerholm S, Salo T, Mauramo M. · J Stomatol Oral Maxillofac Surg · 2026 · cited 0 timessystematic review
- The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and meta-analysis.
Jiang Q, Liu J, Li Z, Zhang C, Dang Q, Tian Y. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Sex, Timing, and Outcomes of Curative-Intent Immunotherapy: A Systematic Review and Meta-Analysis.
Hollinger AM, Gerard CL, Andreas VJ, Roa Diaz ZM, Gillessen S, Michielin O, Pless M, Peters S, Micheloud C, Hayoz S, Özdemir BC, Schmid S. · JAMA Netw Open · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Reshaping the Battlefield: Reprogramming the Melanoma Tumour Microenvironment (TME) by Anti-CTLA-4, Anti-PD-1, and Anti-PD-L1 Monotherapy and Combination Therapy: A Systematic Review and Meta-Analysis of Preclinical and Clinical Evidence.
Karakousis VA, Mantalovas S, Karakousi VC, Vizirianakis IS, Papamitsou T, Pavlidis L, Kosmidis CS. · Cells · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.
Leachman SA, Luke JJ, Ascierto PA, Long GV, Khattak MA, Rutkowski P, Xu ZJ, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Schadendorf D. · JAMA Netw Open · 2026 · cited 1 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Defining and modeling 'cure' in early-stage melanoma: perspectives from a systematic literature review.
Wehler E, Sander J, Boukouvalas S, Black CM. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis.
Dacoregio MI, Rego Castro CED, Mamede I, Rodrigues CG, Thimotheo Batista JP, Michelon I, Ribeiro PZ, Oliveira Junior JR, Bonadio RC, Vilbert M, Barros Costa RL. · Breast · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.
Tetzlaff M, Taube JM, Long GV, Dummer R, Robert C, Menzies AM, Hill A, Gaudy-Marqueste C, Portnoy DC, Lebbe C, Krishnan R, Xu J, Fukunaga-Kalabis M, Krepler C, Scolyer RA. · ESMO Open · 2026 · cited 0 timesOpen accessclinical trial, phase i
- Immunotherapy in urological cancers: new paradigms and a systematic review of clinical trials and real-world evidence.
Ismaili N, El Majjaoui S. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review.
Ismail H, Hassan A. · Front Oncol · 2026 · cited 1 timesOpen accesssystematic review, systematic-review
- Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer-a monocentric experience.
Weber M, Trumet L, Lange F, Murk J, Schubert P, Alsamra H, Backhaus J, Corradini S, Kesting M, Müller S, Morris J, Haderlein M. · Cancer Immunol Immunother · 2026 · cited 0 timesOpen accessclinical trial, phase ii, multicenter study
- MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
Schlaak M, Cimminiello C, Pigozzo J, Lee J, Grabbe S, Rutkowski P, Mackiewicz J, Tsai KK, Ascierto PA, Mandalà M, Carnevale-Schianca F, Haferkamp S, Atkinson V, Hassel JC, Sandhu S, Sharfman W, Dean E, Noor U, Iyer S, Rabbie R, Ribas A. · Clin Cancer Res · 2026 · cited 0 timesOpen accessclinical trial, phase ii, multicenter study
- Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis.
Surendran HP, Gopisetty G, Rajappa SJ, Rao TS, Unnikrishnan MK. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis.
Araujo DV, Souza BL, Seibel MF, Fares AF, Liutti VT. · Oncologist · 2025 · cited 1 timesOpen accessmeta-analysis, systematic review
- Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis.
Zarańska K, Kamińska-Winciorek G, Cortez AJ, Wąsik G, Gajda M. · Dermatol Ther (Heidelb) · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial.
Merrick S, South A, Frangou E, Rush HL, Patel G, Thompson J, Plant H, Pickering L, Langley RE, Gilbert DC, Powles T, Larkin J, Meade A. · PLoS One · 2026 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.
Ejder P, Jespersen H, Hernberg M, Ny L, Carneiro A, Ellegård S, Mattila K, Bagge RO, Fountoukidis G, Brandberg Y, Mandala M, O Carrigan B, Schilling B, Aranche A, Hamid O, Berglund A, Helgadottir H, Ullenhag G. · BMC Cancer · 2026 · cited 1 timesOpen accessclinical trial protocol
- Immuno-oncology in the perioperative setting: the next frontier in resectable head and neck cancers - a systematic review.
Kapoor A, Gupta A, Sansar B, Mishra BK, Menon N, Shah M, Noronha V, Prabhash K. · BMC Cancer · 2026 · cited 0 timesOpen accesssystematic review, review-article
- A comprehensive review and case series of adjuvant and neoadjuvant therapies in acral melanoma with emerging insights from CT DNA testing.
Rao A, Mathavan A, Mathavan A, Doonan B. · Front Oncol · 2025 · cited 0 timesOpen accesssystematic review, systematic-review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.